Lipoic Acid Eye Drops for Consistent Myopia Progression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myopia are ineffective and lack safety, particularly in controlling myopia progression in children and adolescents, due to the complex pathogenesis and structural differences of the eye, and existing drugs exhibit inconsistent results and potential rebound effects.
Innovation Solution
Lipoic acid and lipoic acid choline ester are used as direct active ingredients to inhibit myopia progression, with topical administration demonstrating superior efficacy and safety compared to systemic methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing myopia treatments (antioxidants like vitamin C, cAMP analogs, atropine sulfate) are used, then some therapeutic effects are observed in specific conditions, but results are inconsistent and show rebound effects upon discontinuation
Solution Approach 1:
The patent changes the chemical parameter from conventional antioxidants (vitamin C) or cAMP analogs to lipoic acid and its derivatives, which have different molecular structures and oxidation-reduction properties. This parameter change enables consistent therapeutic effects across multiple myopia types without rebound effects, resolving the inconsistency problem of existing treatments
Solution Approach 2:
The patent introduces lipoic acid as an intermediary substance that mediates the treatment of myopia through its unique disulfide bond structure and ability to scavenge multiple types of reactive oxygen species. This intermediary approach provides a more universal mechanism that works across different myopia pathologies, improving both reliability and adaptability
2Reliability
If higher concentration of atropine is administered to inhibit myopia onset and development, then therapeutic effect is improved, but rebound effect upon discontinuation occurs
Solution Approach 1:
The patent converts the harmful rebound effect into a beneficial outcome by using lipoic acid's unique mechanism of action. Instead of causing rebound effects like atropine, lipoic acid maintains stable therapeutic effects through its antioxidant and anti-inflammatory properties, transforming the harm of discontinuation into a benefit of sustained treatment efficacy
3Reliability
If topical administration of lipoic acid is used to treat myopia, then safety and efficacy are improved, but drug delivery through ocular barriers remains challenging
Solution Approach 1:
The patent changes the physical-chemical parameters of the drug delivery system by using lipoic acid's lipophilic and hydrophilic dual properties, allowing it to penetrate both lipid and aqueous layers of the ocular barrier. This parameter change enables effective drug delivery through complex ocular barriers while maintaining treatment safety and efficacy
Data Source
Figure 1A~2D
Figure 3~4
Figure 5A~5B
AI summary
The present application relates to a pharmaceutical composition for effectively delaying and treating myopia, and in particular, to a method for treating myopia by using lipoic acid and/or lipoic acid choline ester. The pharmaceutical composition may effectively prevent and control myopia and/or delay myopia progression, while maintaining safety and free of obvious side effects, which results in a good clinical application prospect.